bioAffinity Technologies Q3 net loss widens to $5.28 million; Q3 net revenue falls 26% to $1.07 million

• bioAffinity Technologies’ third-quarter 2026 net loss widened to $5.28 million.
• Revenue fell 26% year over year to $1.07 million, primarily due to lower CyPath Lung reimbursement and fewer laboratory cases.
• Operating expenses rose 23% year over year to $4.58 million.
• CyPath Lung testing revenue climbed 79% year over year to approximately $1.1 million in the first nine months of 2026.
• A collaboration with Pictor will support development and potential commercialization of diagnostic tests for lung inflammation in asthma and COPD patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-050541), on November 06, 2026, and is solely responsible for the information contained therein.